Evidence map›Paper›PMID 41917325›Full record

ArticleEMBO molecular medicine2026

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression.

Thomas Loustau, Ioanna Mitrentsi, Nuohan Wang, Caroline Spenlé, Alexia Pavlidaki, Thibaud Tranchant, Gilles Riegel, Akhil Venu, Rime Oueidat, Manuel Koch and 21 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Thomas Loustau *INSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France. thomas.loustau@unistra.fr.ORCID 0000-0003-4662-5228
Ioanna Mitrentsi *INSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.ORCID 0009-0002-5005-5053
Nuohan WangINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Caroline SpenléINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Alexia PavlidakiINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Thibaud TranchantINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Gilles RiegelINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Akhil VenuINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Rime OueidatINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Manuel KochUniversity Cologne, Faculty of Medicine and University Hospital Cologne, Center for Dental, Oral and Maxillofacial Medicine (central facilities), Cologne, Germany.ORCID 0000-0002-2962-7814
Marion DumasINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Fanny WackINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.
Aurelie HirschlerLaboratoire de Spectrométrie de Masse BioOrganique, Institut Pluridisciplinaire Hubert Curien (IPHC), UMR 7178, Université de Strasbourg, CNRS, Infrastructure Nationale de Protéomique ProFi - UAR2048, Strasbourg, France.
Christine CarapitoLaboratoire de Spectrométrie de Masse BioOrganique, Institut Pluridisciplinaire Hubert Curien (IPHC), UMR 7178, Université de Strasbourg, CNRS, Infrastructure Nationale de Protéomique ProFi - UAR2048, Strasbourg, France.
Nicodème PaulLaboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S 1109, Plateforme GENOMAX, ITI Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France.ORCID 0000-0003-4680-3012
Raphael CarapitoLaboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S 1109, Plateforme GENOMAX, ITI Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France.ORCID 0000-0002-7036-442X
Matthias MörgelinColzyx AB, Lund, Sweden.
Uwe HansenInstitute for Musculoskeletal Medicine (IMM), University Hospital Muenster, Muenster, Germany.
Joyce AzziInstitut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Radiobiology Laboratory, Paul Strauss Comprehensive, Cancer Center, Strasbourg, France.
Lucie AubergeonUniversity of Strasbourg, UPR CNRS 3572, I2CT, 2 allée Konrad Roentgen, Strasbourg, France.
Nathalie SaloméINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.ORCID 0000-0002-0349-0258
Sayda DhaouadiPasteur Institute of Tunis, NanoBioMedika research Team, 13 Place Pasteur - B.P. 74 - 1002, Tunis, Tunisia.
Pierre GrenotLaboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S 1109, Plateforme CYTOMAX, Institut d'Hématologie et d'Immunologie, Strasbourg, France.ORCID 0000-0003-3991-753X
Balkiss Bouhaouala-ZaharPasteur Institute of Tunis, NanoBioMedika research Team, 13 Place Pasteur - B.P. 74 - 1002, Tunis, Tunisia.ORCID 0000-0003-3147-245X
Simona La CioppaArtidis, Hochbergerstrasse 60c, Basel, Switzerland.
Philippe OertleArtidis, Hochbergerstrasse 60c, Basel, Switzerland.
Valerio IzziFaculty of Biochemistry and Molecular Medicine at University of Oulu, Oulu, Finland.ORCID 0000-0002-9960-4917
Marija PlodinecArtidis, Hochbergerstrasse 60c, Basel, Switzerland.
Georges NoelInstitut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Radiobiology Laboratory, Paul Strauss Comprehensive, Cancer Center, Strasbourg, France.ORCID 0000-0003-4952-5572
Hélène BurckelInstitut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Radiobiology Laboratory, Paul Strauss Comprehensive, Cancer Center, Strasbourg, France.
Gertraud OrendINSERM UMR_S 1109, The Tumor Microenvironment Laboratory, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France. gertraud.orend@inserm.fr.ORCID 0000-0003-2522-1195

Funding

Aviesan ITMO Cancer Radio-3RInstitut National Du Cancer (INCa) ECMPACTInstitut National Du Cancer (INCa) FITMANETInstitut National Du Cancer (INCa) TENMAXWorldwide Cancer Research (WCR)/ARC 24-0331
6 · The paper itself

Abstract

Given that head and neck squamous cell carcinoma (HNSCC) patients have poor survival outcomes, a better understanding of the therapeutic benefits of ionizing irradiation (IR), the major treatment modality besides surgery, is needed. A confounding factor is the immunosuppressive tumor microenvironment determined by tenascin-C (TNC), a highly abundant extracellular matrix molecule upregulated by IR. We investigated the roles of TNC on radio-induced tumor regression in a murine oral HNSCC model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, they were radioresistant in TNC genetically depleted mice. We identified fibroblast reticular cells (FRCs) as critical regulators. TNC plays a compartmentalized and dual role in regulating tumor radiosensitivity with a detrimental role in the tumor stroma opposed to an essential role in the tumor-draining lymph nodes. This is relevant as a high FRC signature and high TNC levels together correlate with shorter HNSCC patient survival. TNC-expressing FRCs may be an excellent novel target to improve radiotherapy-induced tumor eradication, as our TNC targeting MAREMO peptide reduced tumor cell numbers and plasticity upon IR.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsTenascinAnimalsDisease Models, AnimalFibroblastsHumansMiceRadiation ToleranceTumor MicroenvironmentTenascinTnc protein, mouseFibroblast Reticular CellsMAREMO PeptideRadiotherapyTenascin-CTumor Draining Lymph Nodes

Identifiers

PMID41917325
PMCPMC13179387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.